European Journal of Applied Physiology, 73, 434-439
Liu J, Tan Y, Zhang H, Zhang Y, Xu P, Chen J, et al
Clinical trial data reveals improvements in insulin sensitivity and glucose metabolism in obese patients treated with tesofensine, with reductions in blood sugar levels observed across all dosage groups
An initial formulation with a fat to protein-plus-carbohydrate ratio of 80:20 demonstrated poor acceptability among participants
75% of the lawsuits listed gastroparesis/stomach paralysis in the complaint, 18% listed ileus, 8% listed gallbladder complications, and 8% listed other severe gastrointestinal conditions
Peptides offer several advantages: Targeted action: Peptides can interact specifically with receptors or pathways relevant to gut repair and immune modulation